GZ 389988

Drug Profile

GZ 389988

Alternative Names: GZ 389988A; GZ389988

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi; Sanofi Genzyme
  • Class Antirheumatics; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Intra-articular, Injection)
  • 01 Nov 2017 Sanofi completes a phase II trial in Osteoarthritis (In the elderly, In adults) in Germany (Intra-articular) (NCT02845271)
  • 31 Jul 2017 Phase-II clinical trials in Osteoarthritis (In the elderly, In adults) in Germany (Intra-articular) before July 2017 (Sanofi pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top